All In Biotech

Drug Trial Radar · NCT04572893

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities

Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

41

Actual

Start

Aug 4, 2020

Primary completion

Feb 22, 2024

Study completion Feb 22, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.

Conditions

  • Primary Familial Dilated Cardiomyopathy

Interventions

  • danicamtivDrug

    Myosin activator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
  2. Number of Participants With Serious Adverse Events (SAEs) in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
  3. Number of Participants With Safety Laboratory Assessments by Intensity in Part ATime frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)
  4. Number of Participants With Clinically Significant Changes in Physical Examinations in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
  5. Number of Participants With Clinically Significant Changes in Vital Signs in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
  6. Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part ATime frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part ATime frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution - 0007

    La Jolla, California

  • Local Institution - 0010

    Washington D.C., District of Columbia

  • Local Institution - 0009

    Tampa, Florida

  • Local Institution - 0002

    Chicago, Illinois

  • Local Institution - 0003

    Boston, Massachusetts

  • Local Institution - 0005

    Rochester, Minnesota

  • Local Institution - 0006

    Cleveland, Ohio

  • Local Institution - 0019

    Columbus, Ohio

  • Local Institution - 0001

    Philadelphia, Pennsylvania

  • Local Institution - 0004

    Charleston, South Carolina

  • Local Institution - 0008

    Germantown, Tennessee

  • Local Institution - 0018

    Austin, Texas

  • Local Institution - 0015

    Würzburg, Germany

  • Local Institution - 0014

    Heidelberg, Baden-Wurttemberg, Germany

  • Local Institution - 0012

    A Coruña, Spain

  • Local Institution - 0011

    El Palmar, Spain

  • Local Institution - 0013

    Majadahonda, Spain

  • Local Institution - 0016

    London, United Kingdom

  • Local Institution - 0017

    Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.